• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    PCI Pharma Services

    test company saurabh

    Adare Pharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Almac Group

    Reed-Lane

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Supply Chain House of Cards

    The COVID-19 pandemic exposes pressures on extended global supply chains

    The Supply Chain House of Cards
    Emil W. Ciurczak, DoraMaxx Consulting04.01.20
    Prior to current international events—namely, the COVID-19 pandemic—I was contemplating how extended and global the pharmaceutical industry has become. Concurrently, so has the supply chain needed to fuel a functioning industry. Looking back at 1970, when I joined Ciba Pharmaceuticals, the paradigm for producing and distributing pharmaceutical products was quite simple:

    1. All raw materials, such as lactose, starch and talc, and organic chemicals—API starting materials and preservatives—for synthesis were, as they now say about produce, “locally sourced.” That simply means made in the USA and overseen by the US FDA and US DA, so, in short, safe and readily available. Lactose came from Midwestern dairy farms, talc from a mine in Alabama, etc.
    
    2. Packaging materials (bottles, caps, cotton, strip-packs) were also locally manufactured by numerous smaller, specialized companies and readily available.
    
    3. APIs were (mostly) generated in-house; then purified and assayed, in-house. So, they were always available and known to be safe and pure.

    4. The commercial product was made in-house using self-made APIs, was bottled (and labeled) in-house, and stored and shipped from in-house warehouses, and shipped directly to pharmacies, doctors, and hospitals.

    So, what changed the paradigm? Many factors, but two of the largest were the 1) rise of mergers and acquisitions. I experienced this when Ciba merged with Geigy in 1972-1973; and 2) blockbuster drugs became the “soup-de-jour.” The mergers began in earnest with the Ciba-Geigy merger, and continued for well over two decades. Some of the reasons, and consequences, of M&A’s and blockbusters were:

    1. Mergers happened to, among other reasons, avoid having to bring products from Europe (Basel, largely, for Ciba, Geigy, and Sandoz; now all part of Novartis). Making all the products at smaller U.S. sites, in light of increasing sales and increasing populations, was difficult, so companies wanted to add production and R&D capabilities—merging is less expensive and faster than building from scratch.

    2. Multiple locations became available to manufacture common products, so any break-downs or weather conditions did not delay deliveries from any single-sourced location. This came in handy when the Ciba-based union went on strike, so critical products could be produced at non-union former Geigy locations.

    3.  As the production of “product A” spread to multiple sites, the demand for API synthesis precluded organic synthesis labs at each location and existing production capacity at existing sites was strained to the point of having short-fall, so we engaged third-party synthesis labs to fill the need.

    4. As production sites spread around the world (well over 80 sites for Pfizer, alone, at the height of Pharma’s growth cycle), local raw materials were incorporated into the products. Pfizer presented a paper on the amount of work needed to assure comparative magnesium stearate supplies. And that is merely one small component.

    5. When blockbuster drugs, e.g., Lipitor, exploded on the scene—followed by the many generics jumping into the game, when patents expired—there was no question of single sources for raw materials. Production facilities needed to keep working, so “equivalent” sources were found in whichever country they existed. This proliferation included labels, cotton filler, bottles and sprayers, and blister packages; all locally sourced (at first).

    “OK,” you might say, “is this a good or bad thing?” My answer is “yes.” While that may sound like a “Schrödinger’s cat” to you, it simply means that very few things, meant to help an industry, are either, or both, depending on circumstances. There are some good points (obviously, or they wouldn’t be in business) to a specialized, extended supply chain:

    1. A “widget” made by a specialist will almost always be better-made and less expensive than were it made by a “Swiss Army knife” company, which makes many widgets. Why?
      a. Not having to change tooling between products adds to speed of delivery.
      b. Making one item allows the factory to streamline the process and make a superior product.
      c. Experience with that single widget tends to make them better and faster as time (and many lots) goes by.
    
    2. Having a constant supply of the dozens of the ingredients of a pharmaceutical product makes them more readily available and made to specification:
      a. Powdered API and excipients for tablets, capsules, creams, and solutions
      b. Containers for solids and liquids
      c. Specialized packaging
        i. Monthly distribution packs for birth control tablets
       ii. Spray pumps for everything from throat sprays for sore throats to dosing inhalable insulin.
      iii. Packages where parts or components of a working applicator are enclosed.

    3. Making the “same” or nearly the same parts for an entire industry keeps the unit price well below what building them in-house would cost. Also, the myriad number of tools and skills required for self-construction would add a great deal to the overall cost of the product.

    4. Potentially, more than one company can make a particular unit for a complex pharmaceutical package, allowing a steady stream to the Pharma company and potentially allowing for price negotiations.

    Now, we get to the flip-over point towards our good/bad scenario. There are very few parts of the supply chain that are per se “bad” (a black or white designation), instead we have over 50 shades of gray. To address some of the more obvious:

    1. Even small companies expect to make a profit. As a consequence, they cannot be expected to share their designs or proprietary manufacturing technologies with competitors. As a consequence, the interchangeability of parts between vendors may not be as seamless as we believe. This means we are more dependent upon a single-source than we might believe. A source 5-10,000 miles distant!

    2. I addressed this point previously, but worth repeating. If we wish to set up a PAT/QbD system for complex products, it is hard enough with simple tablets (controlling/continuously evaluating raw materials, APIs, and auxiliary items, such as capsules or coating liquids/powders), but when you are dealing with dozens of suppliers, potentially in several countries (none of whom are sharing specs), building a PAT or QbD paradigm is very, very problematic.

    The testing and quality programs, in light of an extended supply chain almost obviate any advantages in a working QbD program (almost). Many more safeguards and enforced specifications are needed for imported materials than domestic materials, but even with additional tests on all materials—100% of raw materials has been possible since 1985; I know because I started it—PAT is always worthwhile, if only from a safety perspective, and the bottom line isn’t hurt, either.

    We need to examine all the downsides of an “elastic” supply chain, stretched across the planet. What could possibly go wrong with a 12,000-mile long supply chain?

    1. Political turmoil comes to mind. An uprising in Turkey or a financial crisis in Argentina can cause delays or curtail needed materials for Pharma companies, both large and small. While some events overseas can be predicted and addressed, many are unexpected. For example, a missile from North Korea, flown over Japan, can upset deliveries from South Korea, Japan, or Vietnam.

    2. Then there are “natural” disasters. The volcano in Iceland a few years ago disrupted trade and travel between North America and Europe. Flowers from the Netherlands, unable to reach the U.S. for Valentine’s Day, cost the Dutch flower industry and U.S. florists millions of dollars and resulted in many postponed airplane flights, also costing the industry millions of euros and dollars.
    While this was “localized” to northern Europe and only lasted for a month, the economic effect was considerable. The “ripple effect” in the hospitality industry (restaurants, hotels) was significant.
    
    3. Then there are longer-lasting disasters and disruptions. The Nakashima power plant meltdown, as an example, has been a long-lasting economic drain and will be so for years. The disruption has been local, thanks to government efforts in Japan. But this illustrates how natural disasters can cut any supply chain.

    4. Then there is a force majeure, as we are seeing with the COVID-19 pandemic. Apart from the loss of life and burden on the healthcare system, a general downturn in our economic system, we are seeing the effects of an over-extended supply chain:
      a. The ventilators and facemasks so needed for U.S. patients are in short supply and the major source of these components is, CHINA! And, since the virus first hit China, closing all industry, not only are these not being produced for export, but all existing supplies in China have been diverted to the local population, further exacerbating the world-wide shortages.
      b. Many of the raw materials and APIs needed to fight the effects of COVID-19 also come from areas hardest hit and with travel and work restrictions. So, not only are there health costs, there are monetary ramifications.
        i. If you don’t have materials, you cannot make a product. For example, Apple had to suspend production, because China couldn’t supply screens.
        ii. If you can’t sell products, you cannot make a profit, pay employees (who in turn cannot buy your product), or even keep the lights on.

    So, while long supply chains help bottom lines, we see that any construct—plant, animal, or mechanical—follows a simple rule: the more complex something is, the more easily it can break. 

    Note: China controls most of the rare earth metals used for iPhones, computers, and most defense systems in, for example, Air Force planes and Navy submarines. Should there be a break with them, politically, the full impact of a supply chain would be felt.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • tablets
    • generics
    • covid-19
    • api synthesis

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20


    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20


    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20

    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20


    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20

    • Supply Chain
      What We Have is Failure to Communicate

      What We Have is Failure to Communicate

      When it comes to implementing track and trace technology, why is Pharma dragging its feet?
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.20


    • Vision: 2020

      Vision: 2020

      You have exactly 366 days in 2020 to bring your clarity of vision to reality.
      Ben Locwin 01.28.20

    • Solid Dosage/Creams/Ointments
      The “Greening” of Solid Dosage Form Manufacturing

      The “Greening” of Solid Dosage Form Manufacturing

      Going “green” can mean saving big bucks for pharma manufacturers.
      Emil W. Ciurczak, DoraMaxx Consulting 11.20.19

    • When Life Gives You Lemons…Raise Your Drug Prices

      When Life Gives You Lemons…Raise Your Drug Prices

      The hidden effect of economic models on global drug supply and shortages.
      Ben Locwin 11.20.19

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • ICON Acquires Medpass
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Arkema Reports Full-year 2020 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Christie Brinkley Joins SBLA Beauty
    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Happi

    Latest Breaking News From Happi

    Sales More Than Double at Madison Reed
    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex set to install first PicoJet digital press in US
    Epson hosting workshop at Natural Products Expo virtual event series
    INX International providing relief to Texas
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    H&V Announces Price Increase
    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login